advertisement
5.2 Primates (17)
Showing records 1 to 17
Display all abstracts in classification 5.2 Primates
Search within classification 5.2 Primates78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Fuwa M
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Iwamura R
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78164 Intracranial pressure and glaucoma: Is there a new therapeutic perspective on the horizon?
Wostyn P
Medical Hypotheses 2018; 118: 98-102
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Iwamura R
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Toris CB
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78164 Intracranial pressure and glaucoma: Is there a new therapeutic perspective on the horizon?
Van Dam D
Medical Hypotheses 2018; 118: 98-102
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Tanaka M; Okanari E
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Fan S
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78164 Intracranial pressure and glaucoma: Is there a new therapeutic perspective on the horizon?
De Deyn PP
Medical Hypotheses 2018; 118: 98-102
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Kirihara T
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Taniguchi T
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Odani-Kawabata N
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Ichikawa M; Odani-Kawabata N
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Shams N
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Iwamura R; Iwamura R
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Yoneda K
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Yoneda K; Matsugi T; Shams NK; Zhang JZ
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537